Suppression of generalized seizures activity by intrathalamic 2-chloroadenosine application

Experimental Biology and Medicine

Volumn 230, Issue 7, 2005, Pages 501-505

  Ates, Nurbay ^a   Ilbay, Gul ^a   Sahin, Deniz ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

2 CADO; Pentylenetetrazol; Rat; Thalamus; Theophylline

Indexed keywords

2 CHLOROADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; PENTETRAZOLE; THEOPHYLLINE DERIVATIVE; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; ENERGY METABOLISM; ENZYME ACTIVITY; GRAND MAL EPILEPSY; HYPERPOLARIZATION; MALE; NEUROMODULATION; NONHUMAN; RAT; SCORING SYSTEM; SEIZURE; THALAMUS;

EID: 21544446987     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000709     Document Type: Article

References (34)

1. Ribeiro JA, Sebastiao AM. de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 68:377-392, 2003.
2. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 11:25-36, 2005.
3. During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 32:618-624, 1992.
4. Dragunow M. Endogenous anticonvulsant substances. Neurosci Biobehav Rev 10:229-244, 1986.
5. Herberg LJ, Rose IC, Mintz M. Effect of an adenosine A1 agonist injected into substantia nigra on kindling of epileptic seizures and convulsion duration. Pharmacol Biochem Behav 44:113-117, 1993.
6. Malhotra J, Gupta YK. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rats. Br J Pharmacol 120:282-288, 1997.
7. Gouder N, Fritschy JM, Boison D. Seizure suppression by adenosine Al receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 44:877-885, 2003.
8. Yaar R, Jones MR, Chen JF, Ravid K. Animal models for the study of adenosine receptor function. J Cell Physiol 202:9-20, 2005.
9. Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 362:375-381, 2000.
10. Reppert SM, Weaver DR, Stehle JH, Rivkees SA. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 5:1037-1048, 1991.
11. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468, 1996.
12. Daval JL, Nicolas F, Doriat JF. Adenosine physiology and pharmacology: how about A2 receptors? Pharmacol Ther 71:325-335, 1996.
13. Doriat JF, Koziel V, Humbert AC, Daval JL. Medium- and long-term alterations of brain A1 and A2A adenosine receptor characteristics following repeated seizures in developing rats. Epilepsy Res 35:219-228, 1999.
14. Doriat JF, Koziel V, Humbert AC, Daval JL. Medium- and long-term effects of repeated bicuculline-induced seizures in developing rats on local cerebral energy metabolism. Brain Res 800:114-124, 1998.
15. Pagonopoulou O, Angelatou F, Kostopoulos G. Effect of pentylente-trazol-induced seizures on A1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience 56:711-716, 1993.
16. Miller JW, Hall CM, Holland KD, Ferrendelli JA. Identification of a median thalamic system regulating seizures and arousal. Epilepsia 30:493-500, 1989.
17. Mirski MA, Tsai YC, Rossell LA, Thakor NV, Sherman DL. Anterior thalamic mediation of experimental seizures: selective EEG spectral coherence. Epilepsia 44:355-365, 2003.
18. Mirski MA, McKeon AC, Ferrendelli JA. Anterior thalamus and substantia nigra: two distinct structures mediating experimental generalized seizures. Brain Res 397:377-380, 1986.
19. Inoue M, Duysens J, Vossen JM, Coenen AM. Thalamic multiple-unit activity underlying spike-wave discharges in anesthetized rats. Brain Res 612:35-40, 1993.
20. Velisek L, Kubova H, Pohl M, Stankova L, Mares P, Schickerova R. Pentylenetetrazol-induced seizures in rats: an ontogenetic study. Naunyn Schmiedebergs Arch Pharmacol 346:588-591, 1992.
21. Mirski MA, Rossell LA, Terry JB, Fisher RS. Anticonvulsant effect of anterior thalamic high frequency electrical stimulation in the rat. Epilepsy Res 28:89-100, 1997.
22. Pagonopoulou O, Angelatou F, Kostopoulos G. Effect of pentylentetrazol-induced seizures on A1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience 56:711-716, 1993.
23. Winn HR, Welsii JE, Bryner C, Rubio R, Berne RM. Brain adenosine production during the initial 60 seconds of bicuculline seizures in rats. Acta Neurol Scand 60:536-537, 1979.
24. Dunwiddie TV, Worth T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther 220:70-76, 1982.
25. Fredholm BB. Adenosine and neuroprotection. Int Rev Neurobiol 40:259-280, 1997.
26. Dichter MA. Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia 35(Suppl 4):51-57, 1994.
27. Ilbay G, Sahin D, Karson A, Ates N. Effects of adenosine administration on spike-wave discharge frequency in genetically epileptic rats. Clin Exp Pharmacol Physiol 28:643-646, 2001.
28. Varma MR, Dixon CE, Jackson EK, Peters GW, Melick JA, Griffith RP, Vagni VA, Clark RS, Jenkins LW, Kochanek PM. Administration of adenosine receptor agonists or antagonists after controlled cortical impact in mice: effects on function and histopathology. Brain Res 951:191-201, 2002.
29. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 70:761-845, 1990.
30. De Sarro A, Grasso S, Zappala M, Nava F, De Sarro G. Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmocol 356:48-55, 1997.
31. Gupta YK, Chaudhary G, Srivastava AK. Protective effect of resveratrol against pentylenetetrazole-induced seizures and its modulation by an adenosinergic system. Pharmacology 65:170-174, 2002
32. Zagnoni PG, Bianchi A, Zolo P, Ganger R, Cornaggia C, D'Alessandro P, DeMarco P, Pisani F, Gianelli M, Verze L. Allopurinal as add-on therapy in refractory epilepsy: a double-blind placebo-controlled randomized study. Epilepsia 35:107-112, 1994
33. Parada-Turska J, Czuczwar M, Kis J, Czuczwar P, Cioczek A, Luszczki J, Czuczwar SJ. Allopurinal does not affect the anticonvulsant activity of carbamazepine and valproate in maximal electroshock-induced convulsions in mice. Pol J Pharmacol 56:67-72, 2004
34. Borowicz KK, Luszczki J, Czuczwar SJ. 2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anti-convulsant activity of carbamazepine and clonazepam in mice. Eur Neuropsychopharmacol 12:173-179, 2002.